Status
Conditions
Study type
Funder types
Identifiers
About
The aim of this study is to find out whether a new image analysis technique called Cortical Disarray Measurement (CDM) could be used to help better diagnose Alzheimer's disease. This study will see whether changes on CDM can be used to identify Alzheimer's disease from a group of people living with memory and thinking problems. The study will also explore how CDM relates to changes in memory or thinking over time.
Full description
This is a multi-centre observational longitudinal cohort study to evaluate and optimise the Cortical Disarray Measurement (CDM) technique for diagnosis and prognosis in patients with mild cognitive impairment and prodromal / mild Alzheimer's Disease. CDM is a novel MRI analysis tool that quantifies cortical and regional diffusion tensor imaging signals in grey matter to observe pathological changes related to neurodegeneration. Participants in this study will be monitored for 2 years.
Research Aims:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
PATIENT PARTICIPANTS
Inclusion Criteria:
Exclusion Criteria:
COMPANION PARTICIPANTS
Inclusion Criteria:
Exclusion Criteria:
400 participants in 2 patient groups
Loading...
Central trial contact
Angus Prosser, PhD; Christopher Kipps, MBBS, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal